

Deferiprone Market By Form (Tablets, Others) , By Application (Transfusional Iron Overload, NTDT Caused Overload.) By Distribution Channel (Hospital Pharmacies, Drug store & retail pharmacies, Online providers) : Global Opportunity Analysis and Industry Forecast, 2024-2033

<https://marketpublishers.com/r/D10A72E48841EN.html>

Date: July 2024

Pages: 280

Price: US\$ 2,655.00 (Single User License)

ID: D10A72E48841EN

Abstracts

Deferiprone Market

The deferiprone market was valued at \$33.4 million in 2023 and is projected to reach \$45.9 million by 2033, growing at a CAGR of 3.2% from 2024 to 2033.

Deferiprone is a compound used as a medication for curing iron overload caused by blood transfusions or thalassemia major. The role of deferiprone involves the chelation of iron and its removal from the bloodstream through urine. Deferiprone is consumed as a tablet or oral solution and is readily absorbed by the upper gastrointestinal tract.

The growth of the deferiprone market is significantly driven by increase in the prevalence of diseases that require regular blood transfusions such as thalassemia and sickle cell anemia. In addition, rise in awareness regarding iron disorders is boosting the adoption of deferiprone for iron overload cases. Furthermore, governments in several countries are focusing on the improvement of treatment capabilities for chronic diseases and iron-related disorders, which is upsurging the demand for deferiprone. This is propelling the development of the market. Currently, explorations regarding expansion of the applications of deferiprone are trending in the market. According to an article posted on the American Association for Cancer Research Journals, deferiprone is anticipated to act as an alternative immunotherapeutic drug for the control of

metastatic ovarian cancer.

However, improper or excessive dosage of deferiprone leads to severe side effects such as agranulocytosis and neutropenia, limiting its utility and hampering the growth of the market. Furthermore, the medication faces stringent competition from equally efficient alternatives such as desferrioxamine and deferasirox. This restrains the development of the deferiprone market considerably. Contrarily, rise in the popularity of personalized medicine is projected to present new avenues for the market. Personalized medicine involves providing medications and treatments specifically according to an individual's health and body condition. This is projected to boost the uptake of deferiprone as tailored dosages have minimum possibility of causing side effects to the human body.

Segment Review

The deferiprone market is segmented by form, application, distribution channel, and region. On the basis of form, the market is bifurcated into tablets and others. As per application, it is divided into transfusional iron overload and NTDT caused overload. Depending on distribution channel, it is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of form, the tablets segment dominated the market in 2023.

As per application, the transfusional iron overload segment is anticipated to account for a high market share by 2033.

Depending on distribution channel, the online providers segment is projected to be the highest shareholder throughout the forecast period.

Region wise, North America was the highest revenue generator in the market in 2023.

Competition Analysis

The key players operating in the global deferiprone market include Apotex Inc, Cipla Limited, VHB Life Sciences Limited, Tarik Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Novartis International AG, Chiesi Farmaceutici S.p.A,

Zydus Cadila, Cipla Inc., and Pfizer. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Patient/epidemiology data at country, region, global level

Regulatory Guidelines

Additional company profiles with specific t%li%client's interest

Additional country or region analysis- market size and forecast

Expanded list for Company Profiles

Historic market data

SWOT Analysis

Key Market Segments

By Form

Tablets

Others

By Application

Transfusional Iron Overload

NTDT Caused Overload.

By Distribution Channel

Hospital Pharmacies

Drug store retail pharmacies

Online providers

By Region

North America

U.S.

Canada

Mexico

Europe

France

Germany

Italy

Spain

UK

Rest of Europe

Asia-Pacific

China

Japan

India

South Korea

Australia

Rest of Asia-Pacific

LAMEA

Brazil

South Africa

Saudi Arabia

Rest of LAMEA

Key Market Players

Apotex Inc

Cipla Limited

VHB Life Sciences Limited

Tar%l%Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

Novartis International AG

Chiesi Farmaceutici S.p.A

Zydus Cadila

Cipla Inc.

Pfizer

Contents

CHAPTER 1: INTRODUCTION

- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
 - 1.4.1. Primary Research
 - 1.4.2. Secondary Research
 - 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

- 3.1. Market Definition and Scope
- 3.2. Key Findings
 - 3.2.1. Top Investment Pockets
 - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
 - 3.3.1. Bargaining Power of Suppliers
 - 3.3.2. Threat of New Entrants
 - 3.3.3. Threat of Substitutes
 - 3.3.4. Competitive Rivalry
 - 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
 - 3.4.1. Drivers
 - 3.4.2. Restraints
 - 3.4.3. Opportunities

CHAPTER 4: UROKINASE MARKET, BY TYPE

- 4.1. Market Overview
 - 4.1.1 Market Size and Forecast, By Type
- 4.2. Urokinase Powder
 - 4.2.1. Key Market Trends, Growth Factors and Opportunities

- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Urokinase Solution
 - 4.3.1. Key Market Trends, Growth Factors and Opportunities
 - 4.3.2. Market Size and Forecast, By Region
 - 4.3.3. Market Share Analysis, By Country

CHAPTER 5: UROKINASE MARKET, BY END USER

- 5.1. Market Overview
 - 5.1.1 Market Size and Forecast, By End User
- 5.2. Hospital
 - 5.2.1. Key Market Trends, Growth Factors and Opportunities
 - 5.2.2. Market Size and Forecast, By Region
 - 5.2.3. Market Share Analysis, By Country
- 5.3. Clinics
 - 5.3.1. Key Market Trends, Growth Factors and Opportunities
 - 5.3.2. Market Size and Forecast, By Region
 - 5.3.3. Market Share Analysis, By Country

CHAPTER 6: UROKINASE MARKET, BY REGION

- 6.1. Market Overview
 - 6.1.1 Market Size and Forecast, By Region
- 6.2. North America
 - 6.2.1. Key Market Trends and Opportunities
 - 6.2.2. Market Size and Forecast, By Type
 - 6.2.3. Market Size and Forecast, By End User
 - 6.2.4. Market Size and Forecast, By Country
 - 6.2.5. U.S. Urokinase Market
 - 6.2.5.1. Market Size and Forecast, By Type
 - 6.2.5.2. Market Size and Forecast, By End User
 - 6.2.6. Canada Urokinase Market
 - 6.2.6.1. Market Size and Forecast, By Type
 - 6.2.6.2. Market Size and Forecast, By End User
 - 6.2.7. Mexico Urokinase Market
 - 6.2.7.1. Market Size and Forecast, By Type
 - 6.2.7.2. Market Size and Forecast, By End User
- 6.3. Europe

- 6.3.1. Key Market Trends and Opportunities
- 6.3.2. Market Size and Forecast, By Type
- 6.3.3. Market Size and Forecast, By End User
- 6.3.4. Market Size and Forecast, By Country
- 6.3.5. Germany Urokinase Market
 - 6.3.5.1. Market Size and Forecast, By Type
 - 6.3.5.2. Market Size and Forecast, By End User
- 6.3.6. France Urokinase Market
 - 6.3.6.1. Market Size and Forecast, By Type
 - 6.3.6.2. Market Size and Forecast, By End User
- 6.3.7. UK Urokinase Market
 - 6.3.7.1. Market Size and Forecast, By Type
 - 6.3.7.2. Market Size and Forecast, By End User
- 6.3.8. Italy Urokinase Market
 - 6.3.8.1. Market Size and Forecast, By Type
 - 6.3.8.2. Market Size and Forecast, By End User
- 6.3.9. Spain Urokinase Market
 - 6.3.9.1. Market Size and Forecast, By Type
 - 6.3.9.2. Market Size and Forecast, By End User
- 6.3.10. Rest of Europe Urokinase Market
 - 6.3.10.1. Market Size and Forecast, By Type
 - 6.3.10.2. Market Size and Forecast, By End User
- 6.4. Asia-Pacific
 - 6.4.1. Key Market Trends and Opportunities
 - 6.4.2. Market Size and Forecast, By Type
 - 6.4.3. Market Size and Forecast, By End User
 - 6.4.4. Market Size and Forecast, By Country
 - 6.4.5. Japan Urokinase Market
 - 6.4.5.1. Market Size and Forecast, By Type
 - 6.4.5.2. Market Size and Forecast, By End User
 - 6.4.6. China Urokinase Market
 - 6.4.6.1. Market Size and Forecast, By Type
 - 6.4.6.2. Market Size and Forecast, By End User
 - 6.4.7. Australia Urokinase Market
 - 6.4.7.1. Market Size and Forecast, By Type
 - 6.4.7.2. Market Size and Forecast, By End User
 - 6.4.8. India Urokinase Market
 - 6.4.8.1. Market Size and Forecast, By Type
 - 6.4.8.2. Market Size and Forecast, By End User

- 6.4.9. South Korea Urokinase Market
 - 6.4.9.1. Market Size and Forecast, By Type
 - 6.4.9.2. Market Size and Forecast, By End User
- 6.4.10. Rest of Asia-Pacific Urokinase Market
 - 6.4.10.1. Market Size and Forecast, By Type
 - 6.4.10.2. Market Size and Forecast, By End User
- 6.5. LAMEA
 - 6.5.1. Key Market Trends and Opportunities
 - 6.5.2. Market Size and Forecast, By Type
 - 6.5.3. Market Size and Forecast, By End User
 - 6.5.4. Market Size and Forecast, By Country
 - 6.5.5. Brazil Urokinase Market
 - 6.5.5.1. Market Size and Forecast, By Type
 - 6.5.5.2. Market Size and Forecast, By End User
 - 6.5.6. Saudi Arabia Urokinase Market
 - 6.5.6.1. Market Size and Forecast, By Type
 - 6.5.6.2. Market Size and Forecast, By End User
 - 6.5.7. South Africa Urokinase Market
 - 6.5.7.1. Market Size and Forecast, By Type
 - 6.5.7.2. Market Size and Forecast, By End User
 - 6.5.8. Rest of LAMEA Urokinase Market
 - 6.5.8.1. Market Size and Forecast, By Type
 - 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

- 7.1. Introduction
- 7.2. Top Winning Strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

- 8.1. NDpharm
 - 8.1.1. Company Overview
 - 8.1.2. Key Executives
 - 8.1.3. Company Snapshot

- 8.1.4. Operating Business Segments
- 8.1.5. Product Portfolio
- 8.1.6. Business Performance
- 8.1.7. Key Strategic Moves and Developments
- 8.2. Wanhua Biochem
 - 8.2.1. Company Overview
 - 8.2.2. Key Executives
 - 8.2.3. Company Snapshot
 - 8.2.4. Operating Business Segments
 - 8.2.5. Product Portfolio
 - 8.2.6. Business Performance
 - 8.2.7. Key Strategic Moves and Developments
- 8.3. Jiangxi Haoran Bio-Pharma
 - 8.3.1. Company Overview
 - 8.3.2. Key Executives
 - 8.3.3. Company Snapshot
 - 8.3.4. Operating Business Segments
 - 8.3.5. Product Portfolio
 - 8.3.6. Business Performance
 - 8.3.7. Key Strategic Moves and Developments
- 8.4. Jiangsu Aidea Pharmaceutical
 - 8.4.1. Company Overview
 - 8.4.2. Key Executives
 - 8.4.3. Company Snapshot
 - 8.4.4. Operating Business Segments
 - 8.4.5. Product Portfolio
 - 8.4.6. Business Performance
 - 8.4.7. Key Strategic Moves and Developments
- 8.5. Techpool
 - 8.5.1. Company Overview
 - 8.5.2. Key Executives
 - 8.5.3. Company Snapshot
 - 8.5.4. Operating Business Segments
 - 8.5.5. Product Portfolio
 - 8.5.6. Business Performance
 - 8.5.7. Key Strategic Moves and Developments
- 8.6. Microbic Biosystems Inc
 - 8.6.1. Company Overview
 - 8.6.2. Key Executives

- 8.6.3. Company Snapshot
- 8.6.4. Operating Business Segments
- 8.6.5. Product Portfolio
- 8.6.6. Business Performance
- 8.6.7. Key Strategic Moves and Developments
- 8.7. Livzon Pharmaceutical Group Inc.
 - 8.7.1. Company Overview
 - 8.7.2. Key Executives
 - 8.7.3. Company Snapshot
 - 8.7.4. Operating Business Segments
 - 8.7.5. Product Portfolio
 - 8.7.6. Business Performance
 - 8.7.7. Key Strategic Moves and Developments
- 8.8. Cadila Healthcare Limited
 - 8.8.1. Company Overview
 - 8.8.2. Key Executives
 - 8.8.3. Company Snapshot
 - 8.8.4. Operating Business Segments
 - 8.8.5. Product Portfolio
 - 8.8.6. Business Performance
 - 8.8.7. Key Strategic Moves and Developments
- 8.9. TAJ Pharmaceuticals Limited
 - 8.9.1. Company Overview
 - 8.9.2. Key Executives
 - 8.9.3. Company Snapshot
 - 8.9.4. Operating Business Segments
 - 8.9.5. Product Portfolio
 - 8.9.6. Business Performance
 - 8.9.7. Key Strategic Moves and Developments
- 8.10. Microbix Biosystems Inc
 - 8.10.1. Company Overview
 - 8.10.2. Key Executives
 - 8.10.3. Company Snapshot
 - 8.10.4. Operating Business Segments
 - 8.10.5. Product Portfolio
 - 8.10.6. Business Performance
 - 8.10.7. Key Strategic Moves and Developments

I would like to order

Product name: Deferiprone Market By Form (Tablets, Others) , By Application (Transfusional Iron Overload, NTDT Caused Overload.) By Distribution Channel (Hospital Pharmacies, Drug store & retail pharmacies, Online providers) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Product link: <https://marketpublishers.com/r/D10A72E48841EN.html>

Price: US\$ 2,655.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D10A72E48841EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970